BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.33.0//EN
X-ORIGINAL-URL:https://www.alzalliance.org/
X-WR-CALNAME:Alzheimer's Alliance
X-WR-CALDESC:
X-WR-TIMEZONE:America/Chicago
BEGIN:VTIMEZONE
TZID:America/Chicago
X-LIC-LOCATION:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T030000
RRULE:FREQ=YEARLY;BYMONTH=03;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T010000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-36d7534290610d9b7e9abed244dd2f28@alzalliance.org
DTSTART;TZID=America/Chicago:20261009T100000
DTEND;TZID=America/Chicago:20261009T113000
DTSTAMP:20260623T164240Z
CREATED:20260623
LAST-MODIFIED:20260624
PRIORITY:5
SEQUENCE:3
TRANSP:OPAQUE
SUMMARY:“Doctor, if it were you, which would you choose?” Navigating personal preference questions in anti‐amyloid immunotherapy selection
DESCRIPTION:Dr. Eric Dinnerstein is the director of the UT Tyler Dementia Center and will share his insights with us in his workshop on navigating choices related to the most recent treatments available for slowing Alzheimer’s disease.\nIn his paper of the same name, he writes “The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head‐to‐head comparative data are absent. When confronted with the question “What would you do if you were me?”, clinical providers must balance evidence‐based medicine with the therapeutic alliance.”\nEric Dinnerstein, MD, is a cognitive neurologist specializing in dementia and early cognitive decline who also practices general neurology, caring for adults with a wide range of neurological conditions. He has led a dementia clinic at MaineHealth near Portland for close to 20 years and served as principal investigator for numerous dementia clinical studies and trials.\nRSVP here\n
URL:https://www.alzalliance.org/events/doctor-if-it-were-you-which-would-you-choose-navigating-personal-preference-questions-in-anti%e2%80%90amyloid-immunotherapy-selection/
LOCATION:The Alzheimer's Alliance, 3531 S. Broadway Ave., Tyler, TX, 75701, United States
END:VEVENT
END:VCALENDAR